SETD2 and glioma: In total, 23 SETD2 changes amongst the 19 tumors were detected at a wide range of VAF (range 2–51%); 4 tumors had more than one SETD2 missense mutation, 3 of which were recurrent high grade gliomas, and the fourth a medulloblastoma.